Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations, the most common mechanism of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). The results showed that the sequential strategy was effective in delaying subsequent chemotherapy treatment and were published today in the journal Future Oncology.
According to the study, the median time on treatment for sequential afatinib and osimertinib was 27.6 months. In this broad, real-world population, the clinical benefit was consistent across all patient subgroups, with particularly encouraging results seen in those with exon 19 deletion (Del19)-positive disease (median time on treatment 30.3 months) and Asian patients (median time on treatment 46.7 months). Additionally, the 2 year and 2.5 year overall survival (OS) rates were 78.9% and 68.8%, respectively.1
Among the patients included in this study, 15.3% had a poor performance status at the start of afatinib treatment (as defined by ECOG performance status ≥2), ordinarily precluding them from clinical trials.1
While osimertinib is an effective first-line treatment,2 there is a lack of approved subsequent TKI treatment options, and many patients progress to chemotherapy following osimertinib failure.1 The results suggest that the sequential strategy of afatinib and osimertinib might offer sustained clinical benefit to a substantial number of patients, prolonging the chemotherapy-free treatment period.1
“With more targeted treatment options becoming available, it is important to understand the impact of multiple lines of targeted therapies on patient outcomes,” said Dr. Maximilian J. Hochmair, Medical Oncologist, Department of Respiratory and Critical Care Medicine, Otto Wagner Hospital and coordinating investigator in the trial. “The results of GioTag show that sequential treatment with afatinib and osimertinib is an attractive strategy in patients with EGFR mutation-positive NSCLC, offering a sustained clinical benefit to a substantial number of patients while – importantly – extending the time patients are kept off chemotherapy.”
Dr. Victoria Zazulina, Global Head of Solid Tumour Oncology, Medicine at Boehringer Ingelheim, said, “We saw through a recent global survey published at WCLC that many physicians do not feel they have enough information to make informed treatment decisions on how to make the most of the available targeted treatments for patients with EGFR M+ NSCLC; in the absence of randomised data, real-world evidence may help inform treatment decisions. GioTag is the first global study in EGFR M+ NSCLC looking at the sequencing of targeted therapies as it is used in daily clinical practice. These results will provide more insights on the use of EGFR TKIs, looking beyond first-line to maximise overall longer-term impact of targeted therapies in NSCLC.”
Results of a recent global survey of HCPs’ attitudes about sequencing treatments for EGFR M+ NSCLC patients are available here. Full results from the GioTag study will be presented at an upcoming medical conference later this year.
Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/giotagsequencingresults
For more information, please visit: www.boehringer-ingelheim.com
Media + PR
Phone: +49 6132 – 77 184867
Mobile: +49 (151) 14368601
Fax: +49 6132 – 77 6601
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Bartek Ingredients Expands Leadership Team22.3.2019 01:35:00 EET | Tiedote
Bartek Ingredients Inc. recently completed a 4,000 ton/year capacity expansion for its malic and food-grade fumaric acid production facility, and today it announces the expansion of its leadership team, with the hiring of Jeff Billig as Vice President of Marketing & Business Development and Heinrich G. Schaefer as International Sales Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005785/en/ The global leader in malic and fumaric acid ingredients expands its leadership team. (Photo: Business Wire) Bartek’s investment in both its team and facilities reinforces its position as the leader in malic and fumaric acid globally and aligns with its mission to facilitate growth and increase global reach to better serve existing customers and markets while opening up new ones. Bartek’s addition of Billig and Schaefer lays the foundation for additional resource investment in the near future while rapidly increasing its sa
Hansard Global Plc Selects SaaS-Based Majesco LifePlus Solutions to Transform Their Business21.3.2019 23:30:00 EET | Tiedote
Majesco (NASDAQ:MJCO), a global leader of cloud core insurance software, today announced that Hansard Global plc, a FTSE listed business, selected Majesco Life IllustratePlus, Majesco Life AdminPlus, and Majesco Life DistributionPlus to support its ambitious growth plans. Hansard Global plc, which is headquartered on the Isle of Man, provides innovative financial products and services for financial advisors and their international clients, leveraging the latest technology to deliver an award-winning online proposition and best-in-class service. This is the third UK win announced in the last 12 months, following the launch of the SaaS offering in February of 2016 and has received a hugely positive response from the industry, endorsed by numerous industry awards. Majesco has established itself as a market leader in cloud-based core insurance solutions within the individual life and pensions sector. Ollie Byrne, Chief Strategy Officer at Hansard Global plc, commented “Our current system h
ResMed to Host an Investor Meeting on April 4, 201921.3.2019 23:05:00 EET | Tiedote
ResMed (NYSE: RMD) (ASX: RMD) today announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to respiratory care and out-of-hospital software. Additional information regarding the investor meeting, including the specific time and webcast link for the presentations, will be made available approximately one week prior to the event and may be accessed by visiting http://investor.resmed.com. Space for the event is limited and therefore in-person attendance is available by invitation only. Presentations at the investor meeting will be transmitted by a live webcast, which may be accessed by visiting http://investor.resmed.com. A replay of the webcast will be accessible on our website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible for approximately one year thereafter. Abo
KILL OnMiners Mining Rigs Offering the Biggest Hash-Rate in the Market21.3.2019 22:53:00 EET | Tiedote
Business Wire requests that NewsItemId: 20190320005122, OnMiners press release "OnMiners Mining Rigs Offering the Biggest Hash-Rate in the Market" issued March 20, 2019 be removed. View source version on businesswire.com: https://www.businesswire.com/news/home/20190320005122/en/ Contact information Business Wire, France +33 (0) 1 56 88 29 40
KILL OnMiners Changing the Game in Cryptocurrency Mining21.3.2019 22:51:00 EET | Tiedote
Business Wire requests that NewsItemId: 20190318005779, OnMiners press release "OnMiners Changing the Game in Cryptocurrency Mining" issued March 18, 2019 be removed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005779/en/ View source version on businesswire.com: https://www.businesswire.com/news/home/20190318005779/en/ Contact information Business Wire, France +33 (0) 1 56 88 29 40
Her Excellency Sheikha Hind Attends International Universities Arabic Debating Championship Closing Ceremony21.3.2019 18:03:00 EET | Tiedote
Her Excellency Sheikha Hind bint Hamad Al Thani, Vice Chairperson and CEO of Qatar Foundation (QF), attended the closing ceremony of the fifth edition of the International Universities Arabic Debating Championship (IUDC) organized by QatarDebate, a member of QF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005482/en/ Princess Sumaya University for Technology in Jordan takes First Place (Photo: AETOSWire) The championship – held under the patronage of Her Excellency Sheikha Hind bint Hamad Al Thani – took place at Qatar National Convention Centre from March 16-20, 2019, and included 107 teams from 51 Arab and non-Arab countries. During the ceremony, Her Excellency Sheikha Hind presented the winners with their awards. The debate team from Princess Sumaya University for Technology in Jordan took first place in this year’s edition of IUDC. The boys’ team from Qatar University was awarded second place, while the team from
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme